S F Thomsen1, E C Pritzier2, C D Anderson3, N Vaugelade-Baust4, R Dodge5, A-K Dahlborn6, C Vestergaard7. 1. Department of Dermatology, Bispebjerg Hospital & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. 2. Departement of Dermatology, Stavanger University Hospital, Stavanger, Norway. 3. Divison of dermatology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 4. Novartis Norge AS, Oslo, Norway. 5. Novartis Pharmaceutical A/S, Copenhagen, Denmark. 6. Novartis Sweden AB, Stockholm, Sweden. 7. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Abstract
BACKGROUND: Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CU patients. OBJECTIVE: To examine baseline data from Scandinavian AWARE patients. METHODS: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (≥18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines. Baseline patient characteristics, disease activity (urticaria control test [UCT]), pharmacological treatment, comorbidities and healthcare usage were documented by the treating physician. Quality of life (QoL; dermatology life quality index [DLQI]; chronic urticaria quality of life questionnaire [CU-Q2 oL; Danish patients only]) and work productivity and activity impairment (WPAI) scores were also assessed. RESULTS: Overall, 158 CU patients from seven centres in Denmark (n = 80), Norway (n = 50) and Sweden (n = 28) were included in this baseline analysis. Mean age and BMI were 40.3 years and 26.5 kg/m2 , respectively. The majority of patients were female (69.6%), had uncontrolled CU (75.6%; UCT score <12) and had a 'spontaneous' component to their CU (61.4% CSU; 20.3% both CSU and chronic inducible urticaria). Common comorbidities included asthma (19.6%), allergic rhinitis (16.5%) and food allergies (8.2%). Overall, 60.1% of patients reported using treatments for CU including non-sedative H1-antihistamines (40.5%), corticosteroids (19%), montelukast (14.6%) and omalizumab (8.2%). Pharmacological treatment rates increased to 96.2% during the baseline visit. On average, patient QoL was moderately affected (mean DLQI score 7.7) and healthcare resource usage was high. CONCLUSION: Adult Scandinavian H1-antihistamine-refractory CU patients reported high rates of healthcare usage and QoL impairment. Rates of pharmacological treatment use were low before study enrolment but increased to almost 100% during the baseline visit.
BACKGROUND:Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic UrticariaPatient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CUpatients. OBJECTIVE: To examine baseline data from Scandinavian AWARE patients. METHODS: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (≥18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines. Baseline patient characteristics, disease activity (urticaria control test [UCT]), pharmacological treatment, comorbidities and healthcare usage were documented by the treating physician. Quality of life (QoL; dermatology life quality index [DLQI]; chronic urticaria quality of life questionnaire [CU-Q2 oL; Danish patients only]) and work productivity and activity impairment (WPAI) scores were also assessed. RESULTS: Overall, 158 CUpatients from seven centres in Denmark (n = 80), Norway (n = 50) and Sweden (n = 28) were included in this baseline analysis. Mean age and BMI were 40.3 years and 26.5 kg/m2 , respectively. The majority of patients were female (69.6%), had uncontrolled CU (75.6%; UCT score <12) and had a 'spontaneous' component to their CU (61.4% CSU; 20.3% both CSU and chronic inducible urticaria). Common comorbidities included asthma (19.6%), allergic rhinitis (16.5%) and food allergies (8.2%). Overall, 60.1% of patients reported using treatments for CU including non-sedative H1-antihistamines (40.5%), corticosteroids (19%), montelukast (14.6%) and omalizumab (8.2%). Pharmacological treatment rates increased to 96.2% during the baseline visit. On average, patient QoL was moderately affected (mean DLQI score 7.7) and healthcare resource usage was high. CONCLUSION: Adult Scandinavian H1-antihistamine-refractory CUpatients reported high rates of healthcare usage and QoL impairment. Rates of pharmacological treatment use were low before study enrolment but increased to almost 100% during the baseline visit.
Authors: Simon F Thomsen; Ellen C Pritzier; Chris D Anderson; Siri Juvik; Nicolas V Baust; Rikke Dodge; Anna-Karin Dahlborn; Christian Vestergaard Journal: Acta Derm Venereol Date: 2022-04-07 Impact factor: 3.875
Authors: Marcus Maurer; Ana Giménez-Arnau; Luis Felipe Ensina; Chia-Yu Chu; Xavier Jaumont; Paolo Tassinari Journal: World Allergy Organ J Date: 2020-09-12 Impact factor: 4.084
Authors: Désirée E S Larenas-Linnemann; Claudio A S Parisi; Carla Ritchie; Ricardo Cardona-Villa; Ivan Cherrez-Ojeda; Annia Cherrez; Luis Felipe Ensina; Elizabeth Garcia; Iris V Medina; Mónica Rodríguez-González; Jorge Mario Sánchez Caraballo Journal: Curr Allergy Asthma Rep Date: 2018-05-09 Impact factor: 4.806
Authors: M Maurer; K Houghton; C Costa; F Dabove; L F Ensina; A Giménez-Arnau; G Guillet; G N Konstantinou; M Labrador-Horrillo; H Lapeere; R Meshkova; E A Pastorello; M Velásquez-Lopera; L M Tamayo Quijano; C Vestergaard; N Chapman-Rothe Journal: World Allergy Organ J Date: 2018-11-16 Impact factor: 4.084
Authors: Ivan Cherrez-Ojeda; Marcus Maurer; Jonathan A Bernstein; Emanuel Vanegas; Miguel Felix; German D Ramon; Luis Felipe Ensina; José Ignacio Larco Sousa; Edgar Emilio Matos Benavides; R Cardona Villa; P Latour Staffeld; Blanca María Morfin-Maciel; Jose Mori; Paul Wilches C; Valeria L Mata; Annia Cherrez Journal: World Allergy Organ J Date: 2019-02-23 Impact factor: 4.084
Authors: Misbah Noshela Ghazanfar; Line Kibsgaard; Simon Francis Thomsen; Christian Vestergaard Journal: World Allergy Organ J Date: 2020-01-25 Impact factor: 4.084
Authors: Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; Maximiliano Gomez; Sandra Nora Gonzalez-Diaz; Bryan Martin; Mário Morais-Almeida; Jose Antonio Ortega Martell Journal: World Allergy Organ J Date: 2021-06-01 Impact factor: 4.084